Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 6Cord Blood Stem Cell Transplantation 6fludarabine phosphate 5Cyclosporine 5Mycophenolic Acid 4Whole-Body Irradiation 3Radiotherapy 3Arsenic Trioxide 3Antilymphocyte Serum 3Methylprednisolone 2Methotrexate 2Busulfan 2Azacitidine 2lintuzumab 1fludarabine 1Thiotepa 1Tetradecanoylphorbol Acetate 1Tacrolimus 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Leucovorin 1Hematopoietic Cell Growth Factors 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Cytarabine 1Cholecalciferol 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Anemia, Refractory × lintuzumab × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡